An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD

ClinicalTrials.gov ID: NCT07836647

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07836647. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period.

Study identification

NCT ID: NCT07836647
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Transcend Therapeutics; Industry
Enrollment: 300 participants

Conditions and interventions

Conditions

Post Traumatic Stress Disorder

Interventions

TSND-201 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 25, 2026 (Actual)
Primary completion: Feb 2028 (Estimated)
Completion: Feb 2028 (Estimated)
Last update posted: Nov 3, 2026

2026 – 2028

United States locations

U.S. sites: 9
U.S. states: 5
U.S. cities: 8

Facility	City	State	ZIP	Site status
Mountain View Clinical Research	Denver	Colorado	80209	Recruiting
Bradenton Research Center	Bradenton	Florida	34205	Recruiting
CNS Healthcare	Orlando	Florida	32801	Recruiting
CenExel Tampa	Tampa	Florida	33613	Recruiting
K2 Medical Research Tampa	Tampa	Florida	33634	Recruiting
CenExel Atlanta	Atlanta	Georgia	30331	Recruiting
CenExel Marlton	Marlton	New Jersey	08053	Recruiting
Bio Behavioral Health	Toms River	New Jersey	08755	Recruiting
Cedar Clinical Research	Draper	Utah	84020	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07836647, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 3, 2026 · Synced Nov 15, 2026